Sinopharm Hyundai announced that its holding subsidiary Sinopharm Yixin Pharmaceutical Co., Ltd. received the “Notice of Termination of Drug Registration Application” issued by the State Drug Administration and agreed to Sinopharm Yixin's withdrawal of the registration application for cyclophosphamide injections. Sinopharm submitted the marketing registration application for this product to the State Drug Administration in September 2023 and was accepted. Due to the need to further improve research work, the State Drug Administration recently agreed to withdraw the registration application for this product and terminate the registration process. Up to now, Sinopharm has invested a total of 127.47 million yuan in R&D for cyclophosphamide injections. This withdrawal will not have a significant impact on the company's current operating results.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.